Amolyt Pharma

About:

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.

Top Investors: Andera Partners, Bpifrance, OrbiMed, EQT Life Sciences, Eurazeo

Description:

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Total Funding Amount:

$311M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Écully, Rhone-Alpes, France

Founded Date:

2015-01-01

Contact Email:

contact(AT)alz-pharma.com

Founders:

Thierry Abribat